Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP7 | P09237 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303989 | 0.89 | UGT2B7 (0.48) | UGT2B7PPARGPPARAMEN1CYP1A2 | |
| SCHEMBL19003721 | 0.82 | UGT2B7 (0.48) | UGT2B7MEN1CYP1A2KMT2AAOC3 | |
| SCHEMBL6004972 | 0.82 | UGT2B7 (0.52) | UGT2B7MEN1CYP1A2KMT2AAOC3 | |
| SCHEMBL6317871 | 0.81 | MEN1 (0.57) | UGT2B7HDAC1HDAC8LMNASMN1; SMN2 | |
| SCHEMBL31036064 | 0.81 | MEN1 (0.57) | UGT2B7HDAC1HDAC8LMNASMN1; SMN2 | |
| SCHEMBL27410303 | 0.80 | BCHE (0.47) | UGT2B7MEN1KMT2AAOC3CYP2D6 | |
| SCHEMBL15345330 | 0.79 | SLC2A1 (0.46) | UGT2B7MEN1CYP1A2KMT2AAOC3 | |
| SCHEMBL10582738 | 0.79 | UGT2B7 (0.46) | UGT2B7HDAC1HDAC8NPC1LMNA | |
| SCHEMBL31036013 | 0.79 | SLC2A1 (0.46) | UGT2B7MEN1CYP1A2KMT2AAOC3 | |
| SCHEMBL7496718 | 0.79 | UGT2B7 (0.46) | UGT2B7MEN1CYP1A2KMT2AAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171185-A1 | Indole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD., A JAPANESE CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-6869950-B1 | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-6420409-B1 | GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1142880-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1070705-A1 | INDOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-1020452-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171185-A1 | Indole derivatives | PDE5A, IGFBP5, HTR5A | UGT2B7 1711/4885MMP1 317/4885MMP7 1835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.